Skip to Main Content
Contribute Try STAT+ Today

Barreling forward with its early momentum in the digital therapeutics market, Pear Therapeutics announced Tuesday it will go public via a merger with special purpose acquisition company Thimble Point Acquisition Corp. in a deal valuing Pear at $1.6 billion.

Pear has been at the forefront of making the case to physicians, health systems, insurers, and regulators that software can be medicine for the treatment of all kinds of diseases. Since being founded in 2013, the company has received Food and Drug Administration clearance for three prescription treatments and has built a pipeline of 14 other digital therapeutics. The company hopes to use the proceeds from the deal to expand the reach of its current offerings, advance its research on the rest, and further develop a platform that will enable access to a wide range of software-based medical treatments.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment